Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25317162 | 0.88 | LMNA (0.39) | ALDH1A1TSHRHPGDLMNA | |
| SCHEMBL25313461 | 0.88 | LMNA (0.39) | ALDH1A1TSHRHPGDLMNA | |
| SCHEMBL12539837 | 0.88 | LMNA (0.39) | ALDH1A1TSHRHPGDLMNA | |
| SCHEMBL13629810 | 0.86 | ALDH1A1 (0.49) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10292166 | 0.86 | ALDH1A1 (0.49) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2878783 | 0.83 | ALDH1A1 (0.49) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2880648 | 0.83 | ALDH1A1 (0.49) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL316646 | 0.83 | ALDH1A1 (0.49) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL21193673 | 0.82 | CA12 (0.38) | CA12CA1CA2CA9ALDH1A1 | |
| Bromide SCHEMBL3964464 | 0.82 | ALDH1A1 (0.47) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059690-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2024-02-22 | — | — | US | disclosed |
| CN-101356156-B | Aspartic protease inhibitors | VITAE PHARMACEUTICALS INC | 2012-12-05 | — | — | CN | disclosed |
| WO-2011117254-A1 | PIPERIDINE AMIDES AS MODULATORS OF THE GHRELIN RECEPTOR | PROSIDION LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| CN-101356156-A | Aspartic protease inhibitors | VITAE PHARMACEUTICALS INC (US) | 2009-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059690-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | SIGMAR1, OPRD1, P2RX3 | CA12 4861/4885CA1 3790/4885CA2 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.